Case Report

Benign Metastasizing Leiomyoma of the Uterus: Rare Manifestation of a Frequent Pathology

Maria Inês Raposo1,2, Catarina Meireles3, Mariana Cardoso2, Mariana Ormonde2, Cristina Ramalho1, Monica Pires1, Mariana Afonso3, and Almerinda Petiz1

1Department of Gynecology, Francisco Gentil Portuguese Oncology Institute, Porto, Portugal
2Department of Gynecology, Hospital of Divino Espírito Santo of Ponta Delgada, EPER, São Miguel, Azores, Portugal
3Department of Pathology, Francisco Gentil Portuguese Oncology Institute, Porto, Portugal

Received 26 June 2018; Revised 14 October 2018; Accepted 16 October 2018; Published 30 October 2018

1. Introduction

Uterine leiomyoma is the most common gynecological tumor [1–4]. BML is a rare variant [1–13] characterized by multiple leiomyomatous lesions in distant locations, most commonly the lungs [3–11]. Less frequently involved areas are lymph nodes, inferior vena cava, heart, brain, bones, abdomen, retroperitoneum, pelvis, breast, esophagus, liver, appendix, trachea, skin, muscle, and parametria [14, 15]. The antagonistic terminology of BML reflects the coexistence of benign appearance with a biological behavior suggesting malignancy [2, 3, 8, 16]. When multiple pulmonary nodules are incidentally detected in women with history of surgery for uterine leiomyoma, clinicians should be aware of this potential diagnosis [5, 11, 13].

The incidence of BML remains unclear [6]. Since its first publication by Steiner, in 1939 [18], approximately 150 cases have been published [1]. Due to the rarity of this condition, the pathophysiology and management remains controversial [2, 4]. The literature is scarce on studies regarding the cytogenetic evaluation [7].

Here we report two clinical cases of BML diagnosed in the Portuguese Oncology Institute of Porto (Table 1). Our aim is to review its diagnostic challenges, focusing on clinical, radiological, and anatomopathological findings. We also intend to determine the implications of cytogenetic study of this rare condition. Table 2 summarizes the case reports regarding pulmonary BML recently published in the literature.

2. Case Presentation

2.1. Case 1. A 49-year-old, premenopausal, asymptomatic woman, with past clinical history significant for total hysterectomy 10 years earlier due to a leiomyoma of the uterus, presented with a miliary pattern in a routine chest radiography as in computed tomography (CT) scan (Figure 1). We performed a Positron Emission Tomography (PET) scan that showed weak fluorodeoxyglucose (FDG) uptake in lung nodules. She underwent CT-guided biopsy of a pulmonary nodule which revealed spindle cells consistent with smooth muscle differentiation, without cellular atypia, necrosis, or mitotic figures. Immunohistochemical examination was
### Table 1: Clinical cases.

| Case | Age | Respiration symptoms | Primary surgery for leiomyoma | Radiology | Final diagnosis | Microscopy and Immunohistochemistry | Cytogenetic evaluation | Treatment | Follow-up |
|------|-----|-----------------------|-------------------------------|-----------|-----------------|-------------------------------------|------------------------|------------|-----------|
| 1    | 49  | Asymptomatic          | Total hysterectomy, 10 years ago | Miliary pattern PET: weak FDG uptake | CT-guided biopsy | Smooth muscle tumor, SMA+, desmin +, hormonal receptors+, low Ki-67 | Lung tumor: 19q13 and 22q12 deletions | Bilateral salpingo-oophorectomy and Letrozole. | 9 months, stable |
| 2    | 48  | Cough                 | Multiple pulmonary nodules PET: weak FDG uptake | CT-guided biopsy | Smooth muscle tumor, SMA+, desmin +, hormonal receptors+, low Ki-67 | Lung tumor and primary leiomyoma: 19q13 and 22q12 deletions | Bilateral salpingo-oophorectomy | 6 months, stable |

PET= positron emission tomography; FDG= Fluorodeoxyglucose; CT= computed tomography; SMA= smooth muscle actin.
Table 2: Pulmonary BML case reports.

| Refer            | Age | Respiratory symptoms          | Primary surgery for leiomyoma | Radiology                                      | Final diagnosis                                               | Microscopy and Immunohistochemistry                          | Cytogenetic evaluation | Treatment                                                                 | Follow-up               |
|------------------|-----|-------------------------------|-------------------------------|-----------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|------------------------|----------------------------------------------------------------------------|------------------------|
| Nurettin et al. [1] | 41  | Dyspnea                       | Myomectomy, 10 years ago      | Multiple pulmonary nodules PET: no FDG uptake | VATS biopsy                                                 | Smooth muscle tumor, SMA+, desmin +, hormonal receptors+, low ki-67 | Not applicable          | Bilateral salpingo-oophorectomy, total hysterectomy and Progesterone       | 5 years, stable        |
| Ma et al. [3]    | 45  | Asymptomatic                  | Myomectomy, 11 years ago      | Multiple pulmonary nodules PET: abnormal FDG uptake | Aspiration biopsy                                            | Smooth muscle tumor, SMA+, desmin +, hormonal receptors+, ki-67=1% | Not applicable          | Pulmonary wedge resection                                                  | 5 months, stable       |
| Chen et al. [5]  | 32  | Chest tightness and labored breathing | Myomectomy, 1 month earlier  | Miliary nodules                               | Thoracoscopic Biopsy                                        | Spindle cells, SMA+, desmin +, hormonal receptors+         | Not applicable          | Tamoxifen                                                                 | 3 months, stable       |
| Lee et al. [8]   | 52  | Asymptomatic                  | Vaginal hysterectomy, 10 years ago | Multiple lung cavitations and nodules PET: no FDG avid | Needle Biopsy                                                | Spindle cells, SMA+, desmin +, hormonal receptors+         | Not applicable          | GnRH Agonist                                                               | 15 months, stable      |
| Ras et al. [9]   | 53  | Asymptomatic                  | Myomectomy, 26 years earlier  | Multiple pulmonary nodules                    | Thoracotomy Biopsy                                          | Bland smooth muscle cells, desmin +, hormonal receptors+, low ki-67 | Not applicable          | Subtotal hysterectomy, bilateral salpingo-oophorectomy, removal of the tumors from parametria and appendectomy and pulmonary wedge resection by thoracotomy | Not applicable         |
| Refer                    | Age | Respiratory symptoms                  | Primary surgery for leiomyoma | Radiology                          | Final diagnosis                  | Microscopy and Immunohistochemistry | Cytogenetic evaluation | Treatment                                                                 | Follow-up |
|--------------------------|-----|--------------------------------------|-----------------------------|-----------------------------------|---------------------------------|------------------------------------|------------------------|-----------------------------------------------------------------------------|-----------|
| Ottlakan et al. [10]     | 36  | Asymptomatic                         | Hysterectomy, 7 years earlier | Multiple pulmonary nodules        | Core Biopsy                     | Smooth muscle cells, SMA+           | Lung nodules: 19q22q deletion | Pulmonary wedge resection and cautery resection, through mini-thoracotomy (seven procedures) | Many recurrences |
| Patré et al. [11]*       | 76  | Acute respiratory distress           | Total hysterectomy, 4 years earlier | Multiple pulmonary nodules and pleural effusion | Surgical biopsy | Spindle cells, SMA+, desmin +, hormonal receptors+, caldesmon+ | Not applicable | Resection of pulmonary nodules, removal of trochanteric lesion and aromatase inhibitors | 45 months, stable         |
| Khan et al. [14]         | 47  | Shortness of breath and chest pain   | Cervical hysterectomy, 3 years prior | Multiple pulmonary nodules PET: mild FDG uptake | CT guided biopsy and VATS biopsy | Smooth muscle tumor, SMA+, desmin +, hormonal receptors+, CD34+, CD34, EMA- | Lung nodules: Loss of 19 and 22 and deletion of 1p | VATS wedge resection and anastrozole | 12 months, stable         |
| Bakkensen et al. [15]*   | 46  | Asymptomatic                         | Total hysterectomy, 7 years ago | Multiple pulmonary nodules PET: no FDG uptake | CT guided biopsy | Bland spindle cells, SMA+, desmin +, hormonal receptors+ | Not applicable | Bilateral salpingo-ooforectomy, resection of pelvic mass, opportunistic appendectomy and letrozole | 2 years, stable          |
| Zhong et al. [17]*       | 51  | Asymptomatic                         | Myomectomy, 26 years earlier | Multiple pulmonary nodules PET: abnormal FDG uptake | CT guided biopsy | Spindle-shaped cells, SMA+, desmin +, hormonal receptors+, CD34+, S100-, HMB45-, Ki-67 < 20% | Not applicable | Removal of lumbar spine tumor and Tamoxifen | 5 months, stable          |

* BML of other sites; PET= positron emission tomography; FDG= fluorodeoxyglucose; VATS= video-assisted thoracoscopic surgery; CT= computed tomography; SMA= smooth muscle actin.
positive for smooth muscle actin (SMA), desmin, estrogen, and progesterone receptors and was negative for HBM-45, CK7, and S100. The proliferative index, assessed with Ki-67 index, was low. Cytogenetic evaluation of lung tumor tissue showed 19q and 22q terminal deletions. Cytogenetic analysis of previous leiomyoma was not performed due to insufficient pathological material. After diagnosing BML, patient underwent bilateral salpingo-oophorectomy followed by Letrozole therapy. At 9 months follow-up, there was no further development of the disease.

2.2. Case 2. A 48-year-old premenopausal woman was referred because of persistent cough. Her past clinical history included a hysterectomy 13 years earlier for uterine leiomyoma. Chest radiography and CT revealed multiple pulmonary bilateral nodules (Figure 2) with no FDG uptake in the PET scan. CT-guided biopsy of a pulmonary nodule was performed and the resected uterine leiomyoma was reviewed. Both specimens showed identical histopathology of a low grade, benign appearing, and smooth muscle tumor (Figure 3). The immunohistochemical profile of BML is indistinguishable from that of the primary uterine tumor with positivity for SMA, desmin, estrogen, and progesterone receptors (Figure 4) and negativity for HMB-45, CD31, CD34, and EMA. The staining for ki-67 showed low mitotic activity. Cytogenetic analysis revealed shared profile between both samples, including 19q and 22q terminal deletions (Figure 5). Since these findings were consistent with BML, surgical castration was performed. After 6 months of follow-up, the remaining lesions were stable.

3. Discussion

BML is found primarily in reproductive aged women [2, 5, 11], as in the presented cases. The mean age at diagnosis is 47.3 years [6]. The course of the disease correlates with the level of reproductive hormones [5]. Several theories have been proposed along the years regarding the etiology of BML, including [5–10] hematogenous spread of uterine leiomyoma; in situ proliferation of smooth muscle induced by hormonal stimulation; metastasis of low-grade uterine leiomyosarcoma previously subdiagnosed; peritoneal seeding after surgery for uterine leiomyoma and metaplastic transformation. Since most cases of BML occur from 8.8 to 15 years after gynecological surgery [2, 5, 6, 8], we hypothesize that surgically induced vascular spread is the most likely cause [1, 10]. In addition, we agree with the majority of researchers who consider that BML is clonally derived from uterine leiomyoma [3–8]. The exclusive occurrence in women with history of uterine leiomyoma, the positivity for hormonal receptors, and the susceptibility to antihormonal therapy favor this origin [4, 13]. Overlapping in histopathological, immunohistochemical, and cytogenetic findings between pulmonary and uterine lesions suggests their association [6, 7].

Main clinical symptoms of BML vary depending on the organs involved [15]. Regarding pulmonary BML, patients
are usually asymptomatic [2, 5, 8, 13] and the disease is an incidental finding, as we described in patient 1. Only one-third of patients develop respiratory symptoms, such as cough, hemoptysis, dyspnea, thoracalgia, and respiratory failure [3]. Hemothorax and pneumothorax have also been reported [4, 6].

Imaging findings are not specific for pulmonary BML [4, 5]. Multiple bilateral well-circumscribed pulmonary nodules are found in the majority of patients [1, 2, 8]. Another rarely reported feature is solitary pulmonary nodule, interstitial lung disease, cystic lesions, cavitary lung nodules, and miliary pattern [5, 8, 11]. Radiologic findings of extrapulmonary BML are rarer and less well characterized in the literature.

However, both pulmonary and extra-pulmonary nodules of BML show weak or absent FDG uptake on PET [15]. This allows exclusion of metastasis from uterine sarcoma or extrathoracic malignant tumors [1, 2].

Histopathological confirmation is required for definitive diagnosis of BML [1, 5]. These lesions reveal a smooth muscle phenotype with low mitotic activity, limited vascularization and lacks of anaplasia and necrosis [4–8, 10–13]. Its immunohistochemical features include positivity for smooth muscle actin, desmin, caldesmon, calponin, vimentin [1, 2], and hormonal receptors (estrogen and progesterone receptors) [1, 5]. Low ki-67 index [1, 5] and negativity for HMB-45 [4] are useful for ruling out uterine leiomyosarcoma.
and lymphangioleiomyomatosis, respectively. It is extremely important to differentiate BML from uterine leiomyosarcoma since follow-up and treatment are distinct [5, 8, 13].

Recent genetic studies confirm a shared profile between BML and uterine tumor [6, 7, 12]. The present study contributes to the individualization of BML as a genetically distinct entity, since both patients had 19q and 22q terminal deletions in pulmonary tissue, as previously described by Nucci M. et al. [12]. This cytogenetic profile was found in 3% of uterine leiomyomas, suggesting that BML arises from a biologically distinct minority of leiomyomas [12, 14]. Consequently, these mutations could be used as a marker for uterine leiomyomas with potential to develop BML. Given the rarity of this disease, we do not recommend performing a genetic screening test for all women undergoing surgery due to uterine leiomyoma [6]. However, from our standpoint, searching for 19q and 22q terminal deletions in lung nodules of women with past history of gynecological surgery has a determinant role in the differential diagnosis of BML. Therefore, this genetic study becomes even more useful for BML diagnosis when uterine specimen is unavailable or insufficient for retrospective review [12].

Since BML treatment is not standardized [1, 2, 4] it should be individualized for each patient depending on the metastasis sites [17]. If the disease is resectable, en bloc removal of lesions should be attempted [15, 16]. For pulmonary BML, although primary option consists in surgical excision of the maximum possible number of pulmonary nodules, it may not be technically feasible. Alternative therapies include surgical castration by bilateral oophorectomy, chemical castration [1, 2, 5, 10, 11], or combined therapy [2]. Some researchers advocate expectant treatment in climacteric women [2]. BML usually has an indolent evolution [2, 4] and favorable prognosis [11, 13]. According to the literature, after the excision of intrapulmonary lesions the median survival rate is 94 months [3, 13]. The patients described were re-examined every three months using a pulmonary CT. Although their pulmonary lesions remained stable, an extended follow-up is required to track disease progression.

4. Conclusion

A multidisciplinary approach is crucial for the diagnosis of BML in women with pulmonary smooth muscle neoplasia and history of uterine leiomyoma. The striking resemblance of BML to uterine fibroids should lead to correct diagnosis. When primary uterine tumor cannot be reassessed, the presence of 19q and 22q terminal deletions in lung nodules is strongly predictive of BML [10, 12], promoting proper treatment and surveillance for this benign condition. In the future, new cytogenetic markers may optimize BML diagnosis [7, 9]. Further studies are necessary to clarify the etiology of BML and standardize its management.

Consent

Informed consent has been obtained from the women described for publication of the present clinical cases.

Disclosure

This work was previously presented as a poster at the 25th World Congress on Controversies in Obstetrics, Gynecology, and Infertility (COGI) in 2017.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding publication of this paper.

References

[1] N. AKA, "Benign Pulmonary Metastasizing Leiomyoma of the Uterus," Journal of Clinical and Diagnostic Research, 2016.
[2] S. Chen, Y. Zhang, J. Zhang et al., “Pulmonary benign metastasizing leiomyoma from uterine leiomyoma," World Journal of Surgical Oncology, vol. 11, article no. 163, 2013.
[3] H. Ma and J. Cao, "Benign pulmonary metastasizing leiomyoma of the uterus: A case report," Oncology Letters, vol. 9, no. 3, pp. 1347–1350, 2015.
[4] J. Miller, M. Shoni, C. Siegert, A. Lebenthal, J. Godleski, and C. McNamme, “Benign metastasizing leiomyomas to the lungs: An institutional case series and a review of the recent literature," The Annals of Thoracic Surgery, vol. 101, no. 1, pp. 253–258, 2016.
[5] S. Chen, R.-M. Liu, and T. Li, “Pulmonary benign metastasizing leiomyoma: A case report and literature review," Journal of Thoracic Disease, vol. 6, no. 6, pp. E92–E98, 2014.
[6] E. Barnas, M. Ksią˙zek, R. Ras, A. Skret, J. Skret-Magiero, and E. Dmoch-Gajalarska, “Benign metastasizing leiomyoma: A review of current literature in respect to the time and type of previous gynecological surgery," PLoS ONE, vol. 12, no. 4, 2017.
[7] K. T. Patton, L. Cheng, V. Papavero et al., “Benign metastasizing leiomyoma: clonality, telomere length and clinicopathologic analysis," Modern Pathology, vol. 19, no. 1, pp. 130–140, 2006.
[8] S. R. Lee, Y.-I. Choi, S. J. Lee et al., “Multiple cavitating pulmonary nodules: Rare manifestation of benign metastatic leiomyoma," Journal of Thoracic Disease, vol. 9, no. 1, pp. E1–E5, 2017.
[9] R. Raš, M. Książek, E. Barnaš et al., “Benign metastasizing leiomyoma in triple location: lungs, parametria and appendix," Menopause Review, vol. 2, pp. 117–121, 2016.
[10] A. Otelakian, B. Borda, G. Lazar, L. Tiszlavicz, and J. Furak, “Treatment decision based on the biological behavior of pulmonary benign metastasizing leiomyoma," Journal of Thoracic Disease, vol. 8, no. 8, pp. E672–E676, 2016.
[11] J. Pastré, K. Juvín, B. Grand, L. Gibault, J. Valcke, and D. Israél-Biet, “Pulmonary benign metastasizing leiomyoma presented as acute respiratory distress," Respirology Case Reports, vol. 5, no. 2, 2017.
[12] M. R. Nucci, R. Drapkin, P. D. Cín, C. D. M. Fletcher, and J. A. Fletcher, “Distinctive cytogenetic profile in benign metastasizing leiomyoma: pathogenetic implications," The American Journal of Surgical Pathology, vol. 31, no. 5, pp. 737–743, 2007.
[13] Rokana Taťaf, Sandra Starnes, Jiang Wang et al., "Benign Metastasizing Leiomyoma: A Rare Type of Lung Metastases—Two Case Reports and Review of the Literature," Case Reports in Oncological Medicine, vol. 2014, Article ID 842801, 4 pages, 2014.
[14] M. Khan, A. Faisal, H. Ibrahim, T. Barnes, and G. M. van Otteren, "Pulmonary benign metastasizing leiomyoma: A case
report,” Respiratory Medicine Case Reports, vol. 24, pp. 117–121, 2018.

[15] J. B. Bakkensen, W. Samore, P. Bortoletto, C. C. Morton, and R. M. Anchan, “Pelvic and pulmonary benign metastasizing leiomyoma: A case report,” Case Reports in Women’s Health, vol. 18, p. e00061, 2018.

[16] Y. Kim, K. J. Eoh, J. Lee et al., “Aberrant uterine leiomyomas with extrauterine manifestation: intravenous leiomyomatosis and benign metastasizing leiomyomas,” Obstetrics & Gynecology Science, vol. 61, no. 4, p. 509, 2018.

[17] D. Zong, W. He, J. Li, H. Peng, P. Chen, and R. Ouyang, “Concurrent benign metastasizing leiomyoma in the lung and lumbar spine with elevated standardized uptake value level in positron-emission tomography computed tomography,” Medicine, vol. 97, no. 27, p. e11334, 2018.

[18] P. Steiner, “Metastasizing Fibroleiomyoma of The Uterus - Report of a case and review of the literature,” American Journal of Pathology, vol. 15, no. 1, 1939.